title: Behavioral and neuropharmacological evidence that serotonin crosses the blood-brain barrier in Coturnix japonica (Galliformes; Aves).
abstract: This study was carried out aiming to reach behavioral and neuropharmacological evidence of the permeability of the blood-brain barrier (BBB) to serotonin systemically administered in quails. Serotonin injected by a parenteral route (250-1000 microg x kg(-1), sc) elicited a sequence of behavioral events concerned with a sleeping-like state. Sleeping-like behaviors began with feather bristling, rapid oral movements, blinking and finally crouching and closure of the eyes. Previous administration of 5-HT2C antagonist, LY53857 (3 mg x kg(-1), sc) reduced the episodes of feather bristling and rapid oral movements significantly but without altering the frequency of blinking and closure of the eyes. Treatment with the 5-HT2A/2C antagonist, ketanserin (3 mg x kg(-1), sc) did not affect any of the responses evoked by the serotonin. Quipazine (5 mg x kg(-1), sc) a 5-HT2A/2C/3 agonist induced intense hypomotility, long periods of yawning-like and sleeping-like states. Previous ketanserin suppressed gaping responses and reduced hypomotility, rapid oral movements and bristling but was ineffective for remaining responses induced by quipazine. Results showed that unlike mammals, serotonin permeates the BBB and activates hypnogenic mechanisms in quails. Studies using serotoninergic agonist and antagonists have disclosed that among the actions of the serotonin, feather bristling, rapid oral movements and yawning-like state originated from activation of 5-HT2 receptors while blinking and closure of the eyes possibly require other subtypes of receptors.
authors.affiliation: Departamento de Ciências Fisiológicas, Instituto de Biologia, UFRuralRJ, Seropédica, RJ, Brazil.
authors.forename: P A
authors.initials: PA
authors.lastname: Polo
authors.forename: R O
authors.initials: RO
authors.lastname: Reis
authors.forename: P L
authors.initials: PL
authors.lastname: Cedraz-Mercez
authors.forename: H R
authors.initials: HR
authors.lastname: Cavalcante-Lima
authors.forename: E L
authors.initials: EL
authors.lastname: Olivares
authors.forename: M A
authors.initials: MA
authors.lastname: Medeiros
authors.forename: W S
authors.initials: WS
authors.lastname: Côrtes
authors.forename: L C
authors.initials: LC
authors.lastname: Reis
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism*; D003370:Coturnix; D004305:Dose-Response Relationship, Drug; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D011814:Quipazine / Q000494:pharmacology; D012701:Serotonin / Q000493:pharmacokinetics*; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D012890:Sleep / Q000187:drug effects*; D015000:Yawning / Q000187:drug effects*
chemical_list: D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D012701:Serotonin; D011814:Quipazine; D007650:Ketanserin